Partners
Avectas has entered into a collaborative agreement with The Simon Laboratory at UC Davis, California, USA (UCD) to engage in the characterisation of cells engineered with Avectas’ proprietary, non-viral SOLUPORE® cell engineering platform. Under the collaboration, The Simon Laboratory at UCD will characterise cells engineered using SOLUPORE®, leveraging UCD’s unique cell membrane characterisation expertise and assays. Read More
Avectas has joined the new Competence Center for Next Generation NK Cell-based Cancer Immunotherapy (“NextGenNK”) as a collaborative partner established at Karolinska Institutet (“KI”), Stockholm, Sweden. NextGenNK is scheduled to receive up to approximately $12 million in funding over the next five years from multiple stakeholders including Vinnova, Karolinska Institutet and its industry partners with the opportunity to apply for extended funding for an additional five years at a similar level. Read More
Avectas secured €2.1 million funding under the European Union’s Horizon 2020 programme. Avectas is developing a technology that temporarily makes permeable cells extracted from a patient and allows them to be re-engineered to attack cancers before being infused back into patients. Read More
Become a Partner
Avectas’ SOLUPORE® platform offers a cell engineering solution for next generation cell and gene therapies. Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these lifesaving gene modified cell therapy products.
If you would like to learn more about working with Avectas and our cell engineering technology, get in touch with us.
